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Abstract: Canine mammary carcinoma is the most common cancer among female dogs 
and is often fatal due to the development of distant metastases. In humans, solid tumors are 
made up of heterogeneous cell populations, which perform different roles in the tumor 
economy. A small subset of tumor cells can hold or acquire stem cell characteristics, 
enabling them to drive tumor growth, recurrence and metastasis. In veterinary medicine, 
the molecular drivers of canine mammary carcinoma are as yet undefined. Here we report 
that putative cancer stem cells (CSCs) can be isolated form a canine mammary carcinoma 
cell line, REM134. We show that these cells have an increased ability to form 
tumorspheres, a characteristic of stem cells, and that they express embryonic stem cell 
markers associated with pluripotency. Moreover, canine CSCs are relatively resistant to the 
cytotoxic effects of common chemotherapeutic drugs and ionizing radiation, indicating that 
failure of clinical therapy to eradicate canine mammary cancer may be due to the survival 
of CSCs. The epithelial to mesenchymal transition (EMT) has been associated with cancer 
invasion, metastasis, and the acquisition of stem cell characteristics. Our results show that 
canine CSCs predominantly express mesenchymal markers and are more invasive than 
parental cells, indicating that these cells have a mesenchymal phenotype. Furthermore, we 
show that canine mammary cancer cells can be induced to undergo EMT by TGFβ and that 
these cells have an increased ability to form tumorspheres. Our findings indicate that EMT 
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induction can enrich for cells with CSC properties, and provide further insight into canine 
CSC biology. 
Keywords: canine; breast cancer; cancer stem cell; drug resistance; TGFβ; EMT 
 
1. Introduction  
Mammary tumors are the most common neoplasms that affect female dogs (Canis familiaris), 
constituting half of all tumors in female dogs and from these approximately half are considered 
malignant [1-3]. In both women and dogs, the incidence of mammary tumor development increases 
with age, rarely occurring before 25 and 5 years of age, respectively [4] and is hormone dependent [5]. 
Canine mammary carcinomas have epidemiologic, clinical, morphologic and prognostic features 
similar to those of human breast cancer and therefore represent a comparative model to understand the 
underlying molecular mechanisms of carcinogenesis in both species [4-6].  
Recently, studies have identified subpopulations of cells within tumors that are responsible for 
tumor initiation, growth and metastasis; these cells have been termed cancer stem cells (CSC) [7,8]. 
CSCs have the capacity to self-renew, to initiate and maintain the tumor, and can produce 
heterogeneous lineages of cancer cells to compose the bulk of the tumor [9]. The cancer stem cell 
model therefore proposes that tumor development is akin to abnormal organogenesis [9]. In addition, 
CSCs are resistant to many current cancer treatments, including chemo- and radiation therapy [10-13]. 
Therefore conventional therapies, while killing the bulk of the tumor cells, ultimately fail because they 
do not eliminate the CSC population, which survives to regenerate the tumor. Further understanding 
the properties and mechanisms of CSCs is essential in the development of effective-anti-cancer 
therapies. In humans CSCs were first identified in acute myeloid leukemia [14], and more recently in 
melanomas [15,16], glioblastomas [17] and epithelial cancers [18-22]. In the canine model, we were 
the first to identify CSCs of a canine osteosarcoma cell line [23], and have subsequently isolated CSCs 
from a range of canine solid tumors including glioma, haemangiosarcoma and squamous cell 
carcinoma (data unpublished).  
Recent evidence has suggested that tumor progression and metastasis is dependent upon aberrant 
activation of epithelial to mesenchymal transition (EMT) in cancer cells, resulting in the acquisition of 
invasive and metastatic properties [24]. Classically, EMT is an evolutionarily conserved 
developmental pathway involved in tissue morphogenesis, organ fibrosis and wound healing [25]. The 
hallmark of EMT is the loss of cell surface E-cadherin, which is associated with disassembly of 
adheren junctions, acquired motility and expression of mesenchymal markers including Vimentin and 
Fibronectin [26]. The EMT program is regulated by multiple transcription factors, including Twist, 
Snail and members of the ZFH family [27-29]. It is now known that EMT activation is also associated 
with the maintenance of stem cell properties, and in vitro it has been shown that emergence of CSCs 
occurs as a result of EMT [30-32].  
In this study, we identified and characterized a subpopulation of putative CSCs from a canine 
mammary carcinoma cell line. Distinctive tumorsphere forming ability and expression of embryonic 
stem cell markers were identified in this subset and correlated with intrinsic resistance to DNA 
Cancers 2011, 3              
 
 
1746
damaging drugs and ionizing radiation. This subset of putative CSCs was predominantly mesenchymal 
in terms of marker expression and invasive capacity. In addition we show, for the first time in canine 
cancer cells, TGFβ induction of EMT and subsequent enrichment of cancer stem cells.  
2. Material and Methods 
2.1. Cell Culture and Tumorsphere Formation 
Canine breast cancer derived REM134 cells (a kind gift from Prof. R.W. Else, The University of 
Edinburgh, UK) [33] were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, 
Paisley, UK) supplemented with 10% fetal bovine serum and 100 g/mL streptomycin (Invitrogen, 
Paisley, UK). For anchorage independent culture, REM134 cells were plated as single cells in ultralow 
attachment 6-well plates (Corning, CA, USA) at low cell density (1.5 × 104 cells/mL). Cells were 
grown in serum-free conditional medium, which contained DMEM/F12 supplemented with 
progesterone (20 nM), putrescine (100 μM), sodium selenite (30 nM), transferring (25 μg/mL), insulin 
(20 μg/mL) (Sigma Biochemicals, Dorset, UK), human recombinant bFGF (10 ng/mL) and EGF  
(10 ng/mL) (Peprotech, NJ, USA). Additional growth factors (100 μg/mL) were added to the media 
every other day. All cell cultures were maintained at 37  °C in a humidified CO2 incubator. 
2.2. Tumorsphere Forming Efficiency  
The sphere forming ability of TGFβ treated and untreated cells was determined by resuspending 
cells in serum-free conditional medium at a density of either 6000, 3000 or 1000 cells/well of 6-well 
low adherence plate (Corning, CA, USA). All experiments were conducted in triplicate. Plates were 
maintained at 37 °C in a humidified CO2 incubator and were maintained as before. After 7 days, the 
numbers of colonies were counted in 5 fields per well and representative views were photographed.  
2.3. RNA Extraction and Reverse Transcription PCR Analysis 
Total cellular RNA was extracted using RNeasy® kit (Qiagen, CA, USA) and RNA quality was 
determined by A260 measurement. Semi-quantitative RT-PCR analysis of mRNA expression of stem 
cell specific genes including Oct4, and Nanog was performed using HotStar Taq polymerase (Qiagen, 
CA, USA) and the following specific primers:  
Oct4 sense 5’-CTCTGCAGCCAATCAACCACAA-3’  
antisense 5’-GGAGAGGGGGATGAGAAGTACAAT-3’  
Nanog sense 5’-CTATAGAGGAGAGCACAGTGAAG-3’ 
antisense 5’-GTTCGGATCTACTTTAGAGTGAGG-3’  
β-Actin sense 5’-CATGTTTGAGACCTTCAACACCC-3’ 
antisense 5’-GCCATCTCTTGCTCGAAGTCCAG-3’ 
2.4. Irradiation and Drug Treatments of Cells 
Cells were irradiated in culture media using a Faxitron cabinetX-ray system, 43855D (Faxitron X-
ray Corporation, IL, USA), at a central dose of 2 Gy/min. Cells were irradiated at the stated doses. 
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Cells were treated with Doxorubicin (Pfizer, Sandwich, UK) over the indicated range of concentrations. 
Cells were treated with 10 ng/mL Tgf (Peprotech, NJ, USA) for the indicated times. 
2.5. Protein Detection 
Cells were lysed in urea lysis buffer (7 M urea, 0.1 M DTT, 0.05% Triton X-100, 25 mM NaCl,  
20 mM Hepes pH 7.5). Equal amounts of protein were separated by SDS polyacrylamide gel 
electrophoresis (SDS PAGE), transferred to Hybond-C nitrocellulose membrane (Amersham 
Pharmacia Biotech, Buckinghamshire, UK) and hybridized to an appropriate primary antibody and 
HRP-conjugated secondary antibody for subsequent detection by ECL. Primary antibodies against  
β-actin and Vimentin were purchased from Abcam (Cambridge, UK). Antibodies against -catenin,  
E-Cadherin and Fibronectin were purchased from BD Biosciences (Oxford, UK). Anti-Twist  
(L-21) was purchased from Santa Cruz Biotechnology (CA, USA). Secondary antibodies were  
HRP-conjugated rabbit anti-mouse IgG and swine anti-rabbit IgG, were obtained from 
DakoCytomation (Glostrup, Denmark). 
2.6. Cell Viability Assay 
REM134 cells were seeded in quadruplet in opaque 96-well plates (Corning, CA, USA) at  
500 cells /well. A serial dilution of doxorubicin was added to the appropriate cells the following day. 
Alternatively, cells were treated with different doses of ionizing radiation. Dose-response curves were 
generated 72 hours after exposure. Cytotoxicity was measured using the CellTiter-Glo® Luminescent 
Cell Viability Assay (Promega, Madison, USA), which quantifies the number of viable cells in culture 
based on quantification of ATP present. Data was averaged and normalized against the average signal 
of untreated/vehicle control treated samples. 
2.7. Colony Formation Assay 
Tumorspheres and corresponding adherent parental cells were trypsinised into single cells and 
seeded at 500 cells/10 cm plate. The cells were irradiated at 0 Gy, 1 Gy, 2.5 Gy and 5 Gy whilst in 
suspension. Plates were incubated at 37 °C in humidified CO2 incubator until colonies were visible. 
Growth media was changed once a week. The colonies were fixed by incubating with ice-cold 
methanol for 5 minutes at room temperature. Colonies were stained with Giemsa stain (Sigma-Aldrich, 
Dorset, UK) according to the manufacturer’s instruction, and counted. Each experimental condition 
was assayed in quadruplicate. 
2.8. Invasion Assay 
The invasive ability of cells was determined using the QCM™ collagen-based cell invasion assay 
kit (Millipore, MA, USA) was used according to the manufacturer’s instructions. Cells were seeded 
into the upper inserts at 1 × 105 cells per insert in serum-free DMEM. Cells were incubated at 37 °C 
with 5% CO2 for 48 hours. None invading cells were removed. Cells that migrated through the gel 
insert to the lower surface were stained and quantified by colorimetric measurement at 560 nm. 
Cancers 2011, 3              
 
 
1748
2.9. Wound-induced Migration Assay 
REM134 cells (1 × 106) treated with either TGF (10 ng/mL) or a vehicle control were seeded in 
100 mm culture plates and cultured to at least 95% confluence. Monolayer cells were washed with 
media and then scrapped with a plastic 200 l pipette tip. Cells were then incubated at 37 °C with 5% 
CO2. The “wounded” areas were photographed by phase contrast microscopy at 0, 4, 8, 24, 28, 32 and 
48 hours after scraping. The relative migration distance was calculated by the following formula: 
Relative migration distance (%) = 100 (A-B)/A, where A is the width of the cell wound before 
incubation, and B is the width of the cell wound after incubation. Results are expressed as the  
mean ± standard deviation.  
2.10. Statistical analysis 
The results were presented as the mean ± SD. Data were analyzed using analysis of variance and a 
Student’s t test. p values of <0.05 were considered significant. 
3. Results 
3.1. A Subpopulation of Canine Mammary Carcinoma Cells Have Tumorsphere-forming Capacity  
Previous studies have shown that cancer stem cells derived from a variety of human tumors tend to 
form spheroid colonies in defined serum free culture that favors the proliferation of undifferentiated 
cells [17,34,35]. Here, canine mammary carcinoma cells, REM134, were seeded as single cells at  
low-density into suspension cultures in serum-free growth factor supplemented media (Figure 1A). 
After 5–7 days tumorspheres were clearly visible (Figure 1B) and we estimated that approximately 1% 
of cells give rise to tumorspheres. To determine whether tumorspheres can be expanded in vitro, 
spheres were dissociated into single cell suspensions and passaged multiple times in long-term sphere 
forming assay. These cells repeatedly form tumorspheres for up to sixteen subsequent passages when 
plated under the stated culture conditions and in the absence of attachment.  
To further characterize tumorspheres as a primitive sub-population of REM134 cells, we examined 
the expression of embryonic stem cell markers Oct4 and Nanog. Oct4 and Nanog are transcriptional 
determinants essential for self-renewal and maintenance of the undifferentiated state [36]. Here we 
show that Oct4 and Nanog are expressed at a higher level in tumorspheres compared to parental 
adherent cells (Figure 1C). Thus, the canine mammary carcinoma cell line, REM134, contains a sub-
population of cells that can survive in the absence of attachment, forms tumorspheres that can be 
expanded in vitro, and express embryonic stem cell makers which may be required for maintaining 
these cells in a primitive state. 
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Figure 1. Isolation and characterization of putative cancer stem cells. Tumorsphere 
formation from the REM134 canine mammary carcinoma cell line. Single cells (A) and 
sphere (B). Non-quantitative RT-PCR analysis of mRNA expression of the embryonic 
stem cell markers Oct4 and Nanog (C).  
 
3.2. Canine Mammary Carcinoma Stem Cells Exhibit Greater Resistance to Chemo- and Radiation 
Therapy 
To determine whether tumorspheres cells preferentially survive after treatment with 
chemotherapeutic agents, tumorspheres were dissociated into single cells and treated with increasing 
concentrations of the cancer chemotherapeutic drug, doxorubicin. Doxorubicin is an anti-tumor 
antibiotic DNA damaging agent and is commonly used in veterinary and human cancer chemotherapy 
protocols. We used doses of Doxorubicin in cell culture experiments that correlate to concentrations 
that can be achieved in vivo. Cell viability was assayed 72 hours after treatment. Cells from 
tumorspheres demonstrated a significantly increased resistance to the cytotoxic effect of doxorubicin 
compared to parental adherent cells (Figure 2A).  
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Figure 2. Tumorspheres exhibit increased resistance to conventional chemo- and radiation 
therapies. Adherent cells and tumorspheres were treated with increasing concentrations of 
doxorubicin and cell viability was assayed 72 hours post-treatment ( p = 0.008;  
 p = 0.038; ♯p < 0.001) (A). Radiation sensitivity was determined by assaying for cell 
viability 72 hours post-treatment ( p = 0.003;  p = 0.026;  p = 0.002) (B) and by 
determining colony forming ability ( p = 0.01;  p = 0.009;  p < 0.001) (C). 
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Previously we have shown that tumorspheres derived from this cell line are more resistant to the 
anti-tumor effect of interferon-ω [37], consistent with increased resistance to doxorubicin. In addition, 
we compared the intrinsic radiosensitivity of cells dissociated from tumorspheres and parental adherent 
cells by measuring cell viability and clonogenic analysis. We used radiation doses based upon the 
therapeutic dose range. Adherent cells show a dose dependent decrease in cell viability, whereas 
tumorsphere viability is unaffected with increasing doses of ionizing radiation (Figure 2B). By colony 
formation assay we further confirmed that cells dissociated from tumorspheres are more resistant to 
ionizing radiation than corresponding adherent cells (Figure 2C). We have shown that REM134 cells 
with sphere-forming potential are more resistant to the therapeutic dose of DNA damaging agents and 
ionizing radiation in vitro, and therefore in a physiological setting may contribute to tumor 
repopulation. 
Figure 3. Putative cancer stem cells exhibit mesenchymal characteristics. Tumorspheres 
derived from the REM134 canine mammary carcinoma cell line express mesenchymal 
markers (A). Invasive capacity was assayed using a collagen-based cell invasion assay kit. 
Invading cells are stained (C) and quantified by colorimetric measurement at 560 nm 
( p < 0.008) (B). 
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3.3. Tumorspheres Display Mesenchymal Features and are More Invasive 
The metastatic process involves cell detachment from the extracellular matrix, migration from the 
tumor microenvironment and subsequent invasion and attachment at a secondary site within the body. 
Although the mechanisms underlying tumor cell invasion remain incompletely understood, EMT has 
been implicated by promoting loss of contact inhibition, increased cell motility and enhanced 
invasiveness [26,38]. Here we examined the expression of well-known epithelial markers (E-cadherin 
and -catenin) and mesenchymal markers (Fibronectin and Vimentin) [39]. Tumorspheres were 
dissociated into single cells and compared to parental cells. Western blot analysis showed that the 
expression of E-cadherin and -catenin was significantly decreased, whereas that of Fibronectin and 
Vimentin was significantly increased in tumorspheres compared to parental adherent cells (Figure 3A). 
Therefore tumorspheres that exhibit increased resistance to ionizing radiation and chemotherapy, have 
a mesenchymal phenotype.  
As EMT is associated with increased invasiveness, the invasive capacity of cells dissociated from 
tumorspheres and matched adherent cells was evaluated using the Boyden chamber assay. 
Tumorspheres displayed a significantly greater invasive potential compared to adherent cells  
(Figure 3B and 3C), consistent with the hypothesis that cancer stem cells contribute to invasion and 
migration of the tumor.  
3.4 TGF Treatment of REM134 Cells Induces an Epithelial to Mesenchymal Transition and Enhances 
Tumorsphere Forming Potential  
Previous studies have shown that EMT activation of human neoplastic mammary epithelial cells is 
associated with enrichment of cells with stem-like properties [31]. Here we have shown that canine 
tumorspheres have a mesenchymal phenotype and increased invasiveness, and may have undergone 
EMT. To investigate if an experimentally induced EMT in canine mammary carcinoma cells can also 
result in enrichment of putative cancer stem cells, we treated these cells with TGF, a potent inducer 
of EMT. Within 72 hours of treatment with TGFβ, the cells show a clearly manifested morphological 
change. The untreated cells are characterized by a cobblestone appearance whereas TGFβ treated cells 
have an elongate fibroblastic phenotype indicative of mesenchymal cells (Figure 4A). The 
morphological change is associated with changes in protein expression of molecular markers of EMT. 
In the TGFβ treated cells there is a decrease in the epithelial markers E-cadherin and β-catenin, and an 
up regulation of the mesenchymal markers Fibronectin and Twist (Figure 4B). This data supports the 
hypothesis that TGFβ can activate EMT in canine cells.  
To investigate the effect of TGFβ on cellular migration, monolayer wound-induced migration 
assays were performed. A wound was made in a sub-confluent cell monolayer and cells were allowed 
to migrate into the cell-free area. The distance moved by cells in the untreated and TGFβ treated cells 
was compared. TGFβ treatment significantly enhanced the migration and wound healing capacity of 
REM134 cells (100% closure of the wound in 28 hours) as compared to untreated cells (57% closure in 
28 hours) (Figure 4C and D). Thus, the migratory potential of REM134 cells is enhanced by TGFβ 
treatment. 
Cancers 2011, 3              
 
 
1753
Figure 4. Treatment of canine mammary carcinoma cells with TGFβ can induce an 
epithelial to mesenchymal transition, as indicated by changes in cell morphology (A), 
protein expression levels (B), and increased migration ability ( p = 0.018; ♯p = 0.014;  
p = 0.004; ♯♯p = 0.002; up = 0.001) (C, D). 
 
Cancers 2011, 3              
 
 
1754
EMT activation is proposed to enrich the proportion of cancer stem cells with a given cell 
population. Therefore we tested the ability of TGFβ treated cells to form tumorspheres when grown in 
suspension cultures, as an in vitro measure of cancer stem cell activity. TGFβ treated cells formed 
large clearly identifiable tumorspheres after 7 days in culture (Figure 5A) and showed an ~8-fold 
increase in tumorsphere forming ability relative to untreated cells (Figure 5B). This data indicates that 
canine mammary carcinoma cells induced to undergo an EMT by TGFβ contained a significantly 
greater proportion of cells with a CSC-like phenotype compared to control cells. 
Figure 5. TGFβ treated cells show an increased tumorsphere forming ability compared to 
untreated cells. Tumorspheres resulted less frequently from untreated cells (A), compared 
to cells treated with 10 ng/ml TGFβ (B). The resultant number of spherical colonies were 
counted ( p < 0.001;  p < 0.001;  p < 0.01) (C). 
 
4. Discussion 
Breast cancer is a major cause of morbidity and mortality in women. However, the majority of 
cancer related therapeutic studies rely upon rodent models of human cancer that rarely translate into 
clinical success in human patients [9,40]. Recent advances in veterinary medicine, notably vaccination 
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regimes for once fatal infectious diseases, has led to an increase in age-related diseases of our pet dogs 
and cats which mirrors the pattern of human public health. In the UK, approximately 1 in 3 dogs will 
develop cancer, and with approximately 7 million dogs resident in the UK, this provides an exciting 
opportunity to exploit these cancers in terms of identifying cancer-associated genes, identifying 
environmental risk factors and understanding tumor progression [9]. In contrast to rodent models of 
human cancer, cancers that arise in dogs develop naturally and in the context of an intact immune 
system where tumor, microenvironment and host are syngeneic. Histologically, the majority of human 
cancers are well represented in the canine population, including breast cancer, melanoma, head and 
neck squamous cell carcinoma and osteosarcoma, and follow a similar clinical course [41]. 
Importantly, these observed similarities can be supported with genetic evidence, with the publication 
of the canine genome and the increased portfolio of molecular tools available for this species [42]. For 
example, a recently constructed syntenic karyotype map between humans and dogs demonstrated 
strong similarities in cytogenetic abnormalities in Non-Hodgkin lymphoma occurring in both these 
species [43]. 
With regards to breast cancer, the gene expression profile of metastatic canine mammary 
carcinomas has been determined by utilizing the canine specific affymetrix array. Importantly, this 
expression profile significantly overlaps with expression profiles of metastatic human breast cancer. In 
the subset of overlapping genes there is enrichment of genes associated with cell cycle regulation, 
protein kinases, DNA integrity checkpoint and protein metabolism [44]. In humans, several genes 
predisposing to breast cancer have been identified, but the majority of risk factors remain unknown. 
Even less is known about the inherited risk factors underlying canine mammary tumors. Germ line 
mutations in BRCA1 and BRCA2 account for 5% to 10% of all breast cancer in women [45], and 
correspondingly in dogs, germ line mutations in the same genes, as determined by candidate gene 
association, have also been shown to predispose to canine mammary carcinoma [46]. This recent 
evidence indicates that the molecular drivers and mechanisms of canine and human carcinogenesis are 
analogous. Here we further contribute to the evidence that canine mammary carcinoma is a model 
system that can be used alongside traditional rodent models to study the equivalent human disease. In 
the present study we utilized the REM134 cell line, and report that a subpopulation of canine 
mammary carcinoma cells may be representative of canine cancer stem cells. Putative CSCs were 
characterized by their tumorsphere forming capacity, expression of embryonic stem cell markers and 
resistance to chemo- and radiation therapy. These results are comparable to the human model of 
mammary carcinoma. In future studies we intend to evaluate the in vivo tumorigenic potential of 
isolated canine CSCs, and to investigate if CSCs can be isolated from primary canine breast cancer tissue.  
Breast cancer was the first solid tumor from which CSCs were isolated, and this seminal paper 
provided compelling evidence for the presence of functional heterogeneity within the tumor population 
[18]. CSCs exhibit an ability to undergo self-renewal while sustaining a multipotent differentiation 
capacity to maintain tumor development indefinitely [7,47]. Previous studies have also shown that 
CSCs can be isolated from established cell lines, indicating that they are also maintained in a cellular 
hierarchy [48,49]. Human breast cancer stem cells were initially isolated by high expression of CD44 
and low expression of CD24[18]. We have characterized a diverse range of established canine cancer 
cell lines, including REM134 mammary carcinoma, D17 osteosarcoma, J3T glioma, SB 
haemangiosarcoma, 3132 B-cell Non-Hodgkins lymphoma, and have determined that expression of 
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CD44 in canine cancer cells is cell cycle dependent (data unpublished) and is therefore not 
representative of a CSC marker in this species. However, sphere formation is also an established 
technique used to enrich stem cells [17], and here we show that a subpopulation of canine mammary 
carcinoma cells can promote clonogenic tumorsphere formation and be serially passaged for multiple 
generations. We further characterized tumorspheres using the embryonic stem cell markers, Nanog and 
Oct4. Constitutive expression of the transcription factor Nanog maintains the stem cell phenotype, 
allowing for self-renewal and propagation [50]. Similarly, Oct4 is a POU family transcription factor, 
which is initially expressed in the inner cell mass of the embryo and is essential for the maintenance of 
pluripotency [51]. We found that canine tumorspheres express higher levels of the Oct4 and Nanog 
compared to parental cells. This data supports that tumorspheres have a primitive phenotype and are 
representative of a CSC population.  
After surgery, ionizing radiation and chemotherapy are the most effective therapy for treating both 
human [52] and canine mammary carcinomas, however their effectiveness remains only palliative 
because of the ultimate development of treatment resistance [53,54]. The CSC theory proposes that 
CSCs are inherently resistant to conventional therapies and have the ability to repopulate the tumors 
after treatment [11]. Our results confirmed that tumorspheres derived from a canine mammary 
carcinoma cell line are more resistant to the chemotherapeutic drug doxorubicin and ionizing radiation, 
compared to parental cells. The molecular mechanisms underlying the intrinsic resistance of CSCs to 
conventional therapies remain elusive. However, previous studies have shown that CSCs express high 
levels of drug transporters [55,56]; anti-apoptotic proteins [57,58]; and preferentially activate DNA 
damage pathways[10]; Wnt/-catenin pathways [59] and Akt/PKB survival pathways [60]. 
Interestingly, EMT of tumor cells has also been shown to contribute to drug resistance [25,30,61,62], 
although this remains mechanistically undefined. 
Compelling evidence exists relating EMT to tumor metastasis and more recently to the emergence 
of CSCs. EMT is classically associated with the process of tissue morphogenesis during embryonic 
development, and is characterized by complex changes in gene expression [24]. Thus, epithelial and 
mesenchymal cells can be clearly distinguished by the expression of a number of markers [24]. EMT 
during embryonic development involves the loss of polarity and gain of motile characteristics of 
mesenchymal cells, which has prompted comparisons with metastatic cancer cells during malignant 
progression[63]. Subsequent studies have shown that EMT is a key step towards cancer metastasis, and 
that induction of EMT enhances cancer metastasis through enhanced invasion [64]. Here, we 
characterised tumorspheres and parental adherent cells in the context of EMT markers. We clearly 
show that tumorsphere cells have a mesenchymal phenotype, including down regulation of epithelial 
markers E-cadherin and β-catenin, and up regulation of mesenchymal markers Fibronectin and 
Vimentin, compared to parental adherent cells. Significantly, we also show that tumorspheres are more 
invasive than parental adherent cells, which is also indicative of a mesenchymal phenotype. Our 
findings are coherent with human breast cancers and breast cancer cell lines which display features of 
EMT [65,66], and with recent studies which have reported that loss of E-cadherin expression is 
positively correlated with advanced histological grade, metastasis and decreased survival [67,68].  
Induction of EMT in normal or neoplastic mammary epithelial cells, by TGFβ treatment or siRNA-
mediated inhibition of the human CDH1 gene that encodes E-cadherin, has been shown to result in the 
enrichment of cells with stem-like properties [31,32]. This observation has enabled, for the first time, 
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high-throughput screening to identify compounds with specific activity against CSCs [30]. To our 
knowledge, we are the first to show that TGFβ treatment of canine mammary carcinoma cells can 
induce a change in cell morphology, expression of EMT markers and increased invasiveness consistent 
with induction of an EMT. Significantly, we also show that TGFβ treated canine mammary carcinoma 
cells have enhanced sphere-forming ability, indicating that EMT induction can enrich for canine 
cancer stem cells. CSC populations typically comprise only small minorities of cancer cell populations, 
typically less than 1% [69,70]. Our data confirms that canine CSC populations can be enriched in vitro 
by induction of EMT. This may enable us to further elucidate the mechanisms of CSC biology in the 
context of epigenetic regulation, drug and radiation resistance, and metastasis.  
5. Conclusions 
In summary, our data demonstrates that a putative cancer stem cell population can be isolated from 
a canine mammary carcinoma cell line. We show that these cells express embryonic stem cell markers, 
are invasive and are inherently resistant to radiation and chemotherapy. Significantly, we show that 
EMT induction can enrich the cancer stem cell population, and may be exploited to evaluate novel 
pathways to be targeted to increase therapeutic response in a clinical setting. Our results are consistent 
with human breast cancer models, and ultimately support the use of companion animals as a pre-
clinical model system.  
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